These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 16549859)
1. Telithromycin. Turner M; Corey GR; Abrutyn E Ann Intern Med; 2006 Mar; 144(6):447-8. PubMed ID: 16549859 [No Abstract] [Full Text] [Related]
2. Severe hepatotoxicity of telithromycin. Bertino JS Ann Intern Med; 2006 Sep; 145(6):472; author reply 472. PubMed ID: 16983140 [No Abstract] [Full Text] [Related]
3. Summaries for patients. Telithromycin: a possible cause of severe liver damage? Ann Intern Med; 2006 Mar; 144(6):I42. PubMed ID: 16481450 [No Abstract] [Full Text] [Related]
4. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Clay KD; Hanson JS; Pope SD; Rissmiller RW; Purdum PP; Banks PM Ann Intern Med; 2006 Mar; 144(6):415-20. PubMed ID: 16481451 [TBL] [Abstract][Full Text] [Related]
6. The wobbly status of ketolides: where do we stand? Georgopapadakou NH Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307 [TBL] [Abstract][Full Text] [Related]
7. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Brinker AD; Wassel RT; Lyndly J; Serrano J; Avigan M; Lee WM; Seeff LB Hepatology; 2009 Jan; 49(1):250-7. PubMed ID: 19085949 [TBL] [Abstract][Full Text] [Related]
11. Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study. Batard E; Juvin ME; Jacqueline C; Bugnon D; Caillon J; Potel G; Drugeon HB Antimicrob Agents Chemother; 2005 Jan; 49(1):464-6. PubMed ID: 15616338 [TBL] [Abstract][Full Text] [Related]
12. Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review. Bolesta S; Roslund BP Am J Health Syst Pharm; 2008 Jan; 65(1):37-41. PubMed ID: 18159037 [TBL] [Abstract][Full Text] [Related]
13. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel. Curtiss FR J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515 [No Abstract] [Full Text] [Related]
14. Telithromycin use and spontaneous reports of hepatotoxicity. Dore DD; DiBello JR; Lapane KL Drug Saf; 2007; 30(8):697-703. PubMed ID: 17696582 [TBL] [Abstract][Full Text] [Related]
15. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Chen Y; Guo JJ; Healy DP; Lin X; Patel NC Ann Pharmacother; 2008 Dec; 42(12):1791-6. PubMed ID: 19033479 [TBL] [Abstract][Full Text] [Related]
16. Telithromycin and the FDA: implications for the future. Shlaes DM; Moellering RC Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155 [No Abstract] [Full Text] [Related]
17. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens. Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423 [TBL] [Abstract][Full Text] [Related]
18. Ketek--the FDA perspective. Soreth J; Cox E; Kweder S; Jenkins J; Galson S N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912 [No Abstract] [Full Text] [Related]